Monday, December 11, 2017 10:15 PM ET
The Medicines Company (MDCO) sees Significant Insider buy Extending Trend of purchases over Last Quarter
There was noteworthy buying activity in The Medicines Company shares by an insider today, as revealed in a form 4 document filed with the SEC. One insider — Dr Fredric N Eshelman, Director and Officer — acquired 200,000 shares in the company having a market value of approximately $5,311,000. There have been 2 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been buys resulting in the purchase of 173,215 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net purchases of 373,215 shares and have averaged 124,405 shares per transaction over this time period.
The Medicines Company insider trading represents a higher number of buy/sell trades than for the 16 peer company average over the last 90-day period. The Generic Pharmaceuticals peer group saw 5 buy/sell trades during this period for an average of 0.3 transactions per company. The number of shares per buy/sell trade for The Medicines Company insiders was also higher. Within the peer group there were 176,765 shares purchased and 9,134 shares sold with company insiders having bought 33,526 shares on average.
In determining significant insider buying and selling, trades reported to the SEC that involve awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers have been eliminated in data obtained to create and write this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2017 UpTick Data Technologies. All rights reserved.